Owning discovered the palmitoylation motif of APLNR, we designed a brief substrate sequence to competitively inhibit the palmitoylation of endogenous APLNR. This aggressive peptide, which targets the APLNR palmitoylation web-site together with morphine, can inhibit the development of NCP, which include pain incidence, microglial activation, and inflammatory component release https://williamb951riz6.livebloggs.com/profile